ABSTRACT
We report the interfacial study of a silicon/carbon nanofiber/graphene composite as a potentially high-performance anode for rechargeable lithium-ion batteries (LIBs). Silicon nanoparticle (Si)/carbon nanofiber (CNF)/reduced graphene oxide (rGO) composite films were prepared by simple physical filtration and an environmentally-friendly thermal reduction treatment. The films were used as high-performance anode materials for self-supporting, binder-free LIBs. Reducing graphene oxide improves the electron conductivity and adjusts to the volume change during repeated charge/discharge processes. CNFs can help maintain the structural stability and prevent the peeling off of silicon nanoparticles from the electrodes. When the fabricated Si/CNF/rGO composites were used as anodes of LIBs, the initial specific capacity was measured to be 1894.54 mAh/g at a current density of 0.1 A/g. After 100 cycles, the reversible specific capacity was maintained at 964.68 mAh/g, and the coulombic efficiency could reach 93.8% at the same current density. The Si/CNF/rGO composite electrode exhibited a higher specific capacity and cycle stability than an Si/rGO composite electrode. The Si/CNF/rGO composite films can effectively accommodate and buffer changes in the volume of silicon nanoparticles, form a stable solid-electrolyte interface, improve the conductivity of the electrode, and provide a fast and efficient channel for electron and ion transport.
ABSTRACT
Albumin is one of the most attractive nanoplatforms for targeted imaging and drug delivery due to its biocompatibility and long circulation half-life. However, previously reported albumin-based nanoplatforms have shown inconsistent blood circulation half-life according to the modified methods, and the affecting factors were not well evaluated, which could hamper the clinical translation of albumin-based nanoplatforms. Herein, we developed a finely tuned click-chemistry based albumin nanoplatform (CAN) with a longer circulation half-life and an efficient tumor targeting ability. Methods: CAN was synthesized in two steps. First, albumin was conjugated with ADIBO-NHS (albumin-ADIBO) by reacting albumin with various molar ratios of ADIBO. The number of attached ADIBO moieties was determined using matrix-assisted laser desorption ionization time of flight (MALDI-TOF). Second, the desired modalities including azide-functionalized chelator, a fluorescence dye, and folate were incorporated into albumin-ADIBO using strain-promoted alkyne-azide cycloaddition reaction (SPAAC reaction). The biodistribution and targeting efficiency of functionalized CANs were demonstrated in mice. Results: The degree of functionalization (DOF) and resulting in vivo biodistribution was controlled precisely using the click chemistry approach. Specifically, the numbers of attached azadibenzocyclooctyne (ADIBO) moieties on albumin, the DOF, were optimized by reacting albumin with varying molar ratios of ADIBO with a high reproducibility. Furthermore, we developed a simple and efficient method to estimate the DOF using UV-visible spectrophotometry (UV-vis), which was further validated by matrix-assisted laser desorption ionization time of flight (MALDI-TOF). The biodistribution of CAN could be controlled by DOF, and CAN with an optimized DOF showed a long circulation half-life (> 18 h). CAN was further functionalized using a simple click chemistry reaction with an azide functionalized chelator, a fluorescence dye, and folate. 64Cu- and folate-labeled CAN (64Cu-CAN-FA) showed effective and specific folate receptor targeting in vivo, with an over two-fold higher uptake than the liver at 24 h post-injection. Conclusions: Our development from the precisely controlled DOF demonstrates that an optimized CAN can be used as a multifunctional nanoplatform to obtain a longer half-life with radioisotopes and ligands, and provides an effective method for the development of albumin-based tumor theranostic agents.
